Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...
Lumos Diagnostics has today announced that it has successfully completed the institutional component...
Lumos has been awarded US$2,984,571 from the Biomedical Advanced Research and Development Authority (BARDA)...
Lumos Diagnostics has been awarded placement of their novel POC test, FebriDx®...
Lumos Diagnostics has signed an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific...
Lumos Diagnostics has today announced that it has successfully completed the institutional component...
Lumos CEO, Doug Ward, Chief Financial Officer, Barrie Lambert, and Senior VP Commercial Operations, Paul Kase...
Lumos Diagnostics has released its Quarterly Report & 4C for the period ending 30 June 2024.
Lumos Diagnostics has been included in a Stockhead article spotlighting medtech companies addressing respiratory illness...
In this Q&A with Paul Kase, Lumos’ SVP, Commercial Operations, Paul outlines how Lumos is working in partnership with Henry Schein...
Lumos Diagnostics has extended its agreement with Henry Schein Europe, which will see the expansion of distribution of FebriDx® into Belgium...
FebriDx® - Lumos’ rapid point-of-care test – is now available to health care practitioners in Australia and New Zealand...
Lumos Diagnostics announced this week that it has received US$400,000 payment from Hologic...
Antimicrobial resistance (AMR) is a growing threat to global health, driven largely by the overuse of antibiotics...
Lumos Diagnostics has announced that it has successfully completed the first phase of its Development Agreement...
In this video, Lumos Diagnostics CEO Doug Ward discusses the Company's recent quarterly activity statement and cash flow report...
A wrap-up of Lumos’ performance this Quarter was covered by Foster Stockbroking on ListCorp today...
Lumos is excited to be exhibiting at the 2024 Urgent Care Convention April 13-17...
Lumos is pleased to announce that respected international journal, Infectious Diseases...
Lumos Diagnostics (ASX: LDX) has today announced it has signed an agreement...
The Center for Disease Control has warned of the dangers of antibiotic overuse, which can make...
By entering your email address you are agreeing to our Privacy Policy.
Innovation at the point-of-care
2024 Lumos Diagnostics